December 1, 1990Clinical Neuropharmacology
Low-Molecular-Weight Heparins and Heparinoids and their Use in Acute or Progressing Ischemic Stroke
Key result
Heparinoid Org 10172 shows potential efficacy over standard heparin in acute ischemic stroke.
Why the study?
The heterogeneity of low-molecular-weight heparins has hampered their proper investigation in clinical trials and it is unproven that they have less hemorrhagic and thrombocytopenic risk than conventional heparin in acute ischemic stroke.
Does Org 10172 improve outcomes and lessen mortality compared to standard heparin in patients with acute or progressing ischemic stroke?
Population
Patients with acute or progressing ischemic stroke
Comparison
Low-molecular-weight heparins and heparinoids (Org 10172) vs standard heparin
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Org 10172 should not yet alter acute ischemic stroke management; leaves open comparative efficacy versus heparin pending RCTs.
Structured PICO
Does Org 10172 improve outcomes and lessen mortality compared to standard heparin in patients with acute or progressing ischemic stroke?
P
Population
Patients with acute or progressing ischemic stroke
I
Intervention
Low-molecular-weight heparins and heparinoids (specifically Org 10172)
C
Comparator
Standard heparin
O
Outcome
Outcome and mortality
The LMW heparinoid Org 10172 shows potential for improving outcomes in acute ischemic stroke with less risk of thrombocytopenia than standard heparin, highlighting the need for randomized controlled trials.
Limitations
- Heterogeneity of low-molecular-weight heparins has hampered their proper investigation in clinical trials
Cite This Study
Gordon et al. (1990) conducted a review in Acute or progressing ischemic stroke. Low-molecular-weight heparins and heparinoids (Org 10172) vs. Standard heparin was evaluated. The low-molecular-weight heparinoid Org 10172 shows potential efficacy and safety for acute ischemic stroke compared to standard heparin, but requires validation in a randomized controlled trial.